Clinical research continues to evolve at an impressive pace. Digital technologies streamline data capture, biomarkers deepen biological insight, and innovative trial designs broaden access for diverse populations. These advances have unquestionably accelerated development and expanded participant reach. Still, across all this progress, one dimension consistently shapes outcomes yet remains underrepresented in planning, modeling, and oversight: patient behavior. Behavioral factors like motivation,
placebo response
Cognivia is pleased to announce its participation in the OARSI World Congress 2026, taking place in Florida from April 23 to April 26, 2026. During the event, our team will present new findings on placebo response modelling using psychological characteristics in a remote osteoarthritis trial — an approach that strengthens signal detection and improves the
At the recent 2025 Advanced Technologies & Treatments for Diabetes congress in Amsterdam, Cognivia presented two new scientific posters demonstrating the applicability and scientific robustness of its data-driven tools, Placebell and Compl-AI, in Type 1 Diabetes (T1D) clinical trials. These results mark a significant step forward in addressing two persistent challenges: data variability and patient drop-out, both of which can compromise statistical power
Experts shared their perspectives from real-world trials on both classical and new approaches to manage the placebo response – and some questions arose throughout the discussion.
A growing body of work has demonstrated that pain perception can be modulated by social, cultural, contextual and interpersonal factors.1,2,3,4 Beyond this, patient trust in their doctor – an important component of the doctor-patient relationship – has been shown to positively influence patient health outcomes. A growing body of research is also showing that the placebo effects have
While significant placebo responses rates are often noted in clinical trials for indications like pain and depression, this issue can plague drug development in any therapeutic area – particularly in diseases that rely on subjective or patient-reported outcomes as primary efficacy endpoints. Quality of life (QoL) endpoints, for example, are often used to measure therapeutic efficacy in oncology clinical trials – but also in diseases like schizophrenia, pain, heart failure, inflammatory bowel disease (IBD), allergy and pruritus.